Compare F5 Inc (FFIV) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? F5 Inc trades at $460.11 (market cap $26.97B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: F5 Inc is far larger — about 3.6× Spyre Therapeutics Inc. Common Stock's market cap, and F5 Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FFIV | SYRE | |
|---|---|---|
Market Cap | $26.97B | $7.52B |
Volume | 706,169 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $479.83 | $108.92 |
52-Week Low | $223.99 | $22.18 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $25.61B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $457.26, down 3.43% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.73 surpassing the $4.00 expectation. Revenue grew to $3.09 billion in 2025, and net income margin improved to 21.95%. Recent news highlights F5's leadership in WAAP platforms and AI security innovations, reinforcing its competitive edge.
The outlook remains positive given earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 37.95 suggest premium pricing. Risks include competitive pressures and market volatility. Analyst consensus is mixed with a $416.60 price target below the current price, indicating potential near-term caution despite long-term growth prospects.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
